The model represents an innovative alternative to animal testing for preclinical research, with broad potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development.
The novel model specifically consists of CollPlant’s rhCollagen-based bioinks used for 3D bioprinting and human skin fibroblasts, melanocytes and keratinocytes. The integration of these constructs into a skin-on-a-chip system enables the evaluation of topical and transdermal drug delivery in a non-animal model. In addition, the 3D bioprinting of skin using plant-derived rhCollagen presents significant advantages, including high-throughput production of personalized human skin models, and potential applications in regenerative medicine and other areas of medicine.